You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨騰盛博藥(2137.HK)大漲逾12%再度破頂 市值超360億港元
格隆匯 09-15 11:07
格隆匯9月15日丨騰盛博藥(2137.HK)快速拉昇漲超12%,報51港元再度刷新歷史高價,總市值超360億港元。9月上旬,騰盛博藥宣佈追加1億美元投入,以推進其新冠中和抗體聯合療法BRII-196/198在全球的註冊申請和商業化進程。更早前的8月下旬,公司宣佈了這款聯合療法海外三期臨牀試驗的中期數據,在837例疾病進展高風險的新冠肺炎門診患者中,與安慰劑相比,住院及死亡的複合終點降低78%,具有統計學顯著性。針對國內近期出現的由“德爾塔”變異株引起的新冠病例,騰盛博藥和醫院合作,向廣州、深圳、瑞麗、昆明、南京、揚州、張家界以及鄭州提供BRII-196/BRII-198開展臨牀救治。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account